ICIEM 2021 Symposium: Rare neurometabolic disorders: A focus on aromatic L-amino acid decarboxylase (AADC) deficiency
View the PTC Therapeutics symposium at ICIEM 2021, which reviews clinical and real-life experiences of AADC deficiency and provides an overview of current and potential future management options
Understand the etiology and clinical features of AADC deficiency, and how this differs from other neurotransmitter disorders
Learn from clinical cases that illustrate real-life presentation, key signs and symptoms, and steps to diagnosis
Management approaches for the treatment of AADC deficiency are outlined
Learn about the clinical trial experience of an investigational gene replacement therapy for the treatment of AADC deficiency
This symposium was developed and funded by PTC Therapeutics at ICIEM 2021. It was not part of the official program of ICIEM 2021.
Eladocagene exuparvovec is an investigational gene therapy product currently being developed by PTC Therapeutics for the treatment of patients with deficiency of a protein called AADC. Eladocagene exuparvovec does not currently have a marketing authorization for the treatment of AADC deficiency.
Register now to unlock the content
Register now to access the content on this page
Already registered?
If not, register below
MED-ALL-AADC-2200021 | March 2022
Sign in or register to access exclusive content on this site
Register here to access the content on the site MED-ALL-CORP-2200029 | December 2022
You are now leaving MEDhub, a website provided by PTC Therapeutics. This link will take you to a website to which our Privacy Statement and our Terms and Conditions do not apply.
We encourage you to read the Privacy Policy and the Terms and Conditions of every website you visit. PTC Therapeutics does not endorse and/or influence the content found on websites not owned/operated by PTC Therapeutics.
The content you are trying to access is not currently available.
We will be updating the MEDhub site regularly to provide you with up-to-date, insightful expert-led content. To be notified when new additions become available, register now.